NASDAQ:ANAB AnaptysBio Q1 2025 Earnings Report $66.39 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$66.39 0.00 (0.00%) As of 09:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast AnaptysBio EPS ResultsActual EPS-$1.28Consensus EPS -$1.30Beat/MissBeat by +$0.02One Year Ago EPSN/AAnaptysBio Revenue ResultsActual Revenue$27.77 millionExpected Revenue$15.27 millionBeat/MissBeat by +$12.50 millionYoY Revenue GrowthN/AAnaptysBio Announcement DetailsQuarterQ1 2025Date5/5/2025TimeBefore Market OpensConference Call DateMonday, May 5, 2025Conference Call Time12:00AM ETUpcoming EarningsAnaptysBio's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) AnaptysBio Earnings HeadlinesAnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 10 at 2:28 AM | americanbankingnews.comAnaptysBio Details Tax Treatment of Spin-Off DividendMay 29, 2026 | tipranks.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.July 13 at 1:00 AM | InvestorPlace (Ad)J.P. Morgan Sticks to Its Buy Rating for AnaptysBio (ANAB)May 25, 2026 | theglobeandmail.comAnaptysBio Adjusts Fiscal Year-End and Reporting CalendarMay 21, 2026 | tipranks.comBarclays Remains a Buy on AnaptysBio (ANAB)May 15, 2026 | theglobeandmail.comSee More AnaptysBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AnaptysBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AnaptysBio and other key companies, straight to your email. Email Address About AnaptysBioAnaptysBio (NASDAQ:ANAB) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions. The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders. Among its leading candidates is ANB020, an anti-IL-33 antibody being evaluated for atopic dermatitis and eosinophilic asthma, and ANB019, an anti-IL-36 receptor antibody in development for generalized pustular psoriasis. In addition to its clinical assets, AnaptysBio is advancing several preclinical programs aimed at novel immuno-oncology targets, reflecting its commitment to broadening the therapeutic potential of its platform. AnaptysBio has established strategic partnerships to enhance its research and development efforts. These collaborations include agreements with major pharmaceutical companies to co-develop and commercialize select antibody candidates. Through these alliances, AnaptysBio gains access to expanded development expertise, global regulatory capabilities, and commercialization support, while retaining rights to key programs emerging from its discovery engine. Since completing its initial public offering in 2016, AnaptysBio has grown its team and infrastructure to support both early-stage discovery and late-stage clinical development. The company is led by President and Chief Executive Officer Hamza Suria and maintains research operations in the United States. AnaptysBio’s mission is to deliver differentiated antibody therapeutics that address unmet medical needs in inflammatory diseases and cancer.View AnaptysBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels GrowthPepsiCo’s Dividend Could Turn Patience Into Real Profit Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
